Related Experiment Video
Updated: Aug 5, 2026

Cannula Implantation into the Cisterna Magna of Rodents
Published on: May 23, 2018
Losigamone. Dr Willmar Schwabe
1Department of Neurology, Saint Louis University School of Medicine, MO 63104, USA. willmore@slu.edu
Abstract:
Losigamone is a potential antiepileptic under development by Schwabe, which is currently in phase III clinical trials. By August 2000, Schwabe was seeking suitable partners to collaborate in the completion of the phase III trials and further development. The exact mode of action of losigamone is unclear but it does not involve specific binding of GABA, flunitrazepam or t-butyl-bicyclophosphorothionate (TBPS) to their receptors. Data concerning the interaction of losigamone with GABA-A receptor channels, however, are inconsistent; it does not significantly modify the GABAergic inhibitory postsynaptic potentials (IPSPs) in hippocampal slices, although it potentiates GABA-induced chloride influx in primary spinal cord neuron cultures. Another suggested possible mechanism of action for losigamone is K+ channel activation.
More Related Videos
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Equivalents
Dosage Regimen: Multiple Oral Dosage
Drug Dosing: Obese Patients
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...

